Skip to main content
Clinical Trials/JPRN-UMIN000042226
JPRN-UMIN000042226
Recruiting
未知

Prospective observational study of the efficacy and safety of carbon-ion radiotherapy followed by Nivolumab for primary mucosal malignant melanoma of the head and neck - iROCK-2001H

Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization0 sites34 target enrollmentOctober 26, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
mucosal malignant melanoma of the head and neck
Sponsor
Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization
Enrollment
34
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 26, 2020
End Date
September 30, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Patients with interstitial pneumonia, drug\-induced interstitial lung disease or clinically active interstitial lung disease on chest CT scan 2\)Patients with autoimmune disorders 3\)Known allergy to compounds of similar chemical or biologic composition to Nivolumab 4\)Pregnant or lactating females 5\)Patients in which the physician decides that participation in the study is unsuitable

Outcomes

Primary Outcomes

Not specified

Similar Trials